S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study.

ESMO Open · 2017 · PMC5519807 · PMID 28761727

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

The results of subgroup analyses of OS showed a significant interaction between regimen and number of metastases (1 vs ≥2) and marginally significant interactions between regimen and lung metastases.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.